Abstract
Severe neonatal jaundice (NNJ) remains an important cause of hospitalisation in the first week of life particularly in developing countries where glucose-6-phosphate-dehydrogenase (G6PD) deficiency is prevalent. NNJ is seldom associated with mortality when closely monitored but portends significant long-term risks in settings where hospitals are ill-equipped to provide phototherapy or exchange blood transfusion. Early detection in high-risk populations is an important first step towards redressing the current lack of global initiatives on NNJ. Investment in the development of low-cost bilirubin monitoring devices, functional phototherapy units at first-level health facilities and improved care-seeking practices are also essential, particularly in sub-Saharan Africa.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 22-24 |
| Number of pages | 3 |
| Journal | International health |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Africa
- G6PD
- Global disease burden
- Hyperbilirubinaemia
- Neonatal jaundice
- Perinatal morbidity
Fingerprint
Dive into the research topics of 'Reducing the burden of severe neonatal jaundice in G6PD-deficient populations in low-income countries: are we doing enough?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS